Table 1.
Demographic and clinical characteristics of MDR-TB patients
| Characteristics | Experimental group (N=623) |
|---|---|
|
| |
| Age, years, mean (range) | 42.8 (18−70) |
| Male sex, No. (%) | 447 (71.8) |
| BMI kg/m2, mean (range) | 19.9 (12.57−32.45) |
| Treatment history, No. (%) | |
| New cases | 125 (20.1) |
| Previously treated | 498 (79.9) |
| Treatment duration of previously treated patients (months) | 17.8 (1−40) |
| Co-morbidity, No. (%) | |
| Diabetes | 96 (15.4) |
| Hypertension | 9 (1.4) |
| COPD | 4 (0.6) |
| Cardiopathy | 3 (0.5) |
| Others | 28 (4.5) |
| Course of disease, No. (%) | |
| ≤1 year before | 190 (30.5) |
| >1 year to 3 years before randomization | 155 (24.9) |
| >3 years before randomization | 278 (44.6) |
| Susceptibility test, resistant, No. (%) | |
| Isoniazid | 623 (100.0) |
| Rifampicin | 623 (100.0) |
| Streptomycin | 577 (92.6) |
| Ethambutol | 161 (25.8) |
| Ofloxacin | 124 (19.9) |
| Kanamycin | 85 (13.6) |
Abbreviation: MDR-TB, multidrug-resistant tuberculosis.